Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Boju Pan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9155-9923; OpenAlex author ID A5043705059. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 9

  1. Labor-Efficient Pathological Auxiliary Diagnostic Model for Primary and Metastatic Tumor Tissue Detection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2025.100764↗
  2. Automatic Pancreatic Ductal Adenocarcinoma Detection in Whole Slide Images Using Deep Convolutional Neural Networks. Co-author DOI 10.3389/fonc.2021.665929↗
  3. [Expression and Prognostic Value of Cripto-1 in Pancreatic Cancer]. Co-author DOI 10.3881/j.issn.1000-503x.12734↗
  4. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Co-author DOI 10.1007/s00262-020-02542-7↗
  5. High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.39800↗
  6. β1 and β3 integrins in breast, prostate and pancreatic cancer: A novel implication. Co-author DOI 10.3892/ol.2018.8076↗
  7. Immunoglobulin G4 (IgG4)-positive plasma cell infiltration is associated with the clinicopathologic traits and prognosis of pancreatic cancer after curative re… Co-author DOI 10.1007/s00262-016-1853-2↗
  8. G-protein-coupled receptor kinase 2 in pancreatic cancer: clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.humpath.2016.06.012↗
  9. Cancer-associated fibroblasts in pancreatic adenocarcinoma. Co-author DOI 10.2217/fon.15.176↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Quan Liao · 5 shared papers, 2015–2020 · strength 0.39
  2. Zhiyong Liang · 3 shared papers, 2016–2025 · strength 0.39
  3. Yupei Zhao · 4 shared papers, 2015–2020 · strength 0.33
  4. Huanwen Wu · 2 shared papers, 2020–2025 · strength 0.29
  5. Quan Liao · 2 shared papers, 2020–2021 · strength 0.27
  6. Li Zhou · 3 shared papers, 2015–2020 · strength 0.21
  7. Xiao Ke · 1 shared paper, 2025 · strength 0.21
  8. Xiaoding Liu · 1 shared paper, 2025 · strength 0.21
  9. Junliang Lu · 1 shared paper, 2025 · strength 0.21
  10. Junchao Guo · 2 shared papers, 2018–2020 · strength 0.20
  11. Ming Cui · 2 shared papers, 2020 · strength 0.19
  12. Qiaofei Liu · 2 shared papers, 2016–2020 · strength 0.17
  13. Yu-Pei Zhao · 2 shared papers, 2016–2020 · strength 0.17
  14. Lei You · 2 shared papers, 2016–2020 · strength 0.17
  15. Xiang Gao · 1 shared paper, 2021 · strength 0.16
  16. Qiang Xu · 1 shared paper, 2021 · strength 0.16
  17. Zheyu Niu · 2 shared papers, 2015–2016 · strength 0.13
  18. Mengyi Wang · 2 shared papers, 2016 · strength 0.12
  19. Hao Fu · 1 shared paper, 2021 · strength 0.12
  20. Hao Zou · 1 shared paper, 2021 · strength 0.12
  21. Jing Huang · 1 shared paper, 2020 · strength 0.11
  22. Xiang Zhang · 1 shared paper, 2020 · strength 0.09
  23. Qiaofei Liu · 1 shared paper, 2020 · strength 0.09
  24. Ronghua Zhang · 1 shared paper, 2020 · strength 0.09
  25. Junyi Gao · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.